4.8 Article

Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Mads Delbo Larsen et al.

Summary: This study reveals that afucosylated IgG antibodies are specifically formed against enveloped viruses, but not generally against other antigens. These antibodies enhance Fc gamma RIIIa responses, but also exacerbate cytokine storms and immune-mediated pathologies.

SCIENCE (2021)

Article Biochemistry & Molecular Biology

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler et al.

Summary: This study found that neutralizing human monoclonal antibodies in SARS-CoV-2-infected animals require Fc effector functions for optimal protection, reducing inflammation, improving respiratory mechanics, and being associated with diminished immune signaling and tissue repair.
Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

Article Public, Environmental & Occupational Health

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Review Immunology

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2

Ian McDonald et al.

Summary: This study provides a comparative evaluation of different vaccine platforms in terms of immunogenicity and efficacy. Vaccines generally result in mild and self-limiting adverse events. Different vaccines show varying levels of immunogenicity and efficacy.

NPJ VACCINES (2021)

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Letter Medicine, General & Internal

Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples

Timothy A. Bates et al.

Summary: This study investigates the correlation between age and neutralizing antibody levels against the SARS-CoV-2 USA-WA1/2020 strain and the P.1 variant after receiving 2 doses of the BNT162b2 vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Article Multidisciplinary Sciences

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen et al.

Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.

NATURE COMMUNICATIONS (2021)

Article Immunology

Proinflammatory IgG Fc structures in patients with severe COVID-19

Saborni Chakraborty et al.

Summary: COVID-19 is often characterized by a hyperinflammatory syndrome, and disease severity is associated with specific antibody structures that enhance inflammatory responses.

NATURE IMMUNOLOGY (2021)

Review Geriatrics & Gerontology

COVID-19 and Older Adults: What We Know

Zainab Shahid et al.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2020)

Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Article Multidisciplinary Sciences

Sex differences in immune responses that underlie COVID-19 disease outcomes

Takehiro Takahashi et al.

NATURE (2020)

Article Multidisciplinary Sciences

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

Hannah Peckham et al.

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Article Biochemistry & Molecular Biology

The PRIDE database and related tools and resources in 2019: improving support for quantification data

Yasset Perez-Riverol et al.

NUCLEIC ACIDS RESEARCH (2019)

Review Immunology

Vaccination in the elderly: The challenge of immune changes with aging

Annalisa Ciabattini et al.

SEMINARS IN IMMUNOLOGY (2018)

Review Immunology

Beyond binding: antibody effector functions in infectious diseases

Lenette L. Lu et al.

NATURE REVIEWS IMMUNOLOGY (2018)

Review Immunology

Diversification of IgG effector functions

Stylianos Bournazos et al.

INTERNATIONAL IMMUNOLOGY (2017)

Article Multidisciplinary Sciences

Modulating IgG effector function by Fc glycan engineering

Tiezheng Li et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Article Biochemistry & Molecular Biology

Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy

Taia T. Wang et al.

Review Immunology

Mouse and human FcR effector functions

Pierre Bruhns et al.

IMMUNOLOGICAL REVIEWS (2015)

Review Immunology

The structural basis of antibody-antigen recognition

Inbal Sela-Culang et al.

FRONTIERS IN IMMUNOLOGY (2013)

Article Biochemical Research Methods

Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer

Guoqiang Chen et al.

JOURNAL OF PROTEOMICS (2012)

Article Biochemical Research Methods

Changes in Antigen-specific IgG1 Fc N-glycosylation Upon Influenza and Tetanus Vaccination

Maurice H. J. Selman et al.

MOLECULAR & CELLULAR PROTEOMICS (2012)

Review Transplantation

The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo

Robert M. Anthony et al.

CURRENT OPINION IN ORGAN TRANSPLANTATION (2011)